2215-77-2|4-Phenoxybenzoic acid - Shanghai Canbi Pharma Ltd.

Current Location
Home Products
detail

4-Phenoxybenzoic acid | CAS:2215-77-2

4-Phenoxybenzoic acid

Name：4-Phenoxybenzoic acid
CAS：2215-77-2
Synonyms：
Molecular Formula：C₁₃H₁₀O₃
Molecular Weight：214.22
EINESC：218-682-5

Description

Properties

Melting point	160-164 ºC

Safety

Symbol(GHS)	Xi
Hazard Codes	R36/37/38
SDS/MSDS	S26;S37/39

SDS

Source	SDS/MSDS Samples
Alfa-Aesar	View & Download
Sigma-Aldrich	View & Download
TCI	View & Download

Synthetic Route

Name	CAS
PCI-32765	936563-96-1	View

Articles

Peer-Reviewed Papers

Chemokine co-receptor CCR5/CXCR4-dependent modulation of Kv2.1 channel confers acute neuroprotection to HIV-1 glycoprotein gp120 exposure.Andrew J Shepherd et al.PloS one, 8(9), e76698-e76698 (2013-10-03) Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.Chun-Hui Zheng et al.Cell biology international, 42(10), 1386-1394 (2018-07-05) Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.Miodrag Dragoj et al.Investigational new drugs, 35(6), 718-732 (2017-07-25) CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.Thomas A Werner et al.British journal of cancer, 117(12), 1837-1845 (2017-11-08) Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.Miodrag Dragoj et al.Cellular oncology (Dordrecht), 40(1), 47-62 (2016-11-09)

Remarks

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).

RelatedAPI's

Name	CAS
PCI-32765	936563-96-1	View

Description

Properties

Safety

SDS

RelatedAPI's

Related Products

Related News